Tocilizumab in HIV patient with severe COVID-19: case report

BACKGROUND: A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. CASE PRESENTATION: The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition....

Descripción completa

Detalles Bibliográficos
Autores principales: Bertozzi, Pedro Vieira, de Oliveira Vicente, Amanda, Pereira, Amanda Siqueira, de Sant’Ana, Joao Pedro Espinha, Mano, Rafaela Braga Cabrera, Jorge, Luciana Souza, da Silva Sardenberg, Rodrigo Afonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520187/
https://www.ncbi.nlm.nih.gov/pubmed/34656134
http://dx.doi.org/10.1186/s12981-021-00404-5
Descripción
Sumario:BACKGROUND: A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. CASE PRESENTATION: The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition. Intubation, hemodialysis, and tracheostomy were necessary to maintain homeostasis. In addition to regular treatment with etravirine, dolutegravir, darunavir, and ritonavir for highly active antiretroviral therapy, the patient received tocilizumab, which showed a great recovery in the patient’s condition. CONCLUSION: The patient had several risk factors, such as male gender, age  >  70 years, and arterial hypertension. The use of tocilizumab was of great importance in the patient’s recovery since the drug increased his immune response, which is deficient, due to HIV infection.

Ejemplares similares